📈 Technical Chart Patterns & Trend Analysis 📉 Identifying potential trading opportunities based on trend analysis: bullish divergence can be seen oh 4h time frame
its been a while reasons for pump: after a long downtrend, price has formed a base above a 3 day demand block. price has had a bullish reaction off a triple tap of support (triple bottom). base looks to be accumulation with a bullish divergence on the daily RSI. unusually high v EMA's are beginning to turn upwards after much consolidation. looking to play the...
No insiders. Looking for entry above 6.83, First target 7.83, Stop signal 6.33, 2nd target momentum.
$AFMD Target 9.62 for 28.27% Or double position at 5.38 This one filled in pre-market… That's a pretty decent looking chart... — On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average. I start every position with 1% of my account and build from there as needed and as...
Contextual immersion trading strategy idea. Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. The demand for shares of the company looks higher than the supply. This and other conditions can cause a rise in the share price in the next days. So I...
Bullish Pennant (46%) Pros: Volume during post formation Descending volume during triangle formation PPS above 50MA and 200MA RS above 0 and ascending ATR Ascending R/R ratio above 6 250RSI above 50 and ascending 200MA ascending Target: PT = 12.10$ Help how ever you can to keep this alive. Thank you to those who have donated Coins! Always do your own due...
Entry price: 5.21 Fundamentals: Sector: Medical EPS % Chg (Last Qtr): 58% 3 Year EPS Growth Rate: 0% EPS Est % Chg (Current Yr): 0% Sales % Chg (Last Qtr): 440% 3-Year Sales Growth Rate: 163% Annual Pre -Tax Margin: -151.3%
$AFMD subdued an early session sell off, recovering +7.78% intraday closing above the previous day's closing at $6.79. During the month, AFMD have successfully exhibited a major MA golden cross (50D vs 100D) before the breakout to its 52 weeks high, following with a +21% runaway gap closing on Monday's market session. At the current juncture, $AFMD will be...
AFMD macd bullish cross over signal. Target 1: 4.33 (+10% 70% probability of touchc within next 30 days). Second target: 4.88 30 days expected move: 1.77
Affimed NV engages in discovering and developing of targeted cancer immunotherapies. Its pipelines include Innate Cell Engagers and T Cell Engagers. The company was founded in 2000 and is headquartered in Heidelberg, Germany.
Affimed NV engages in discovering and developing of targeted cancer immunotherapies. Its pipelines include Innate Cell Engagers and T Cell Engagers. The company was founded in 2000 and is headquartered in Heidelberg, Germany.
Real biotech with tangible results in the field of oncology.
AFMD: Affimed N.V. 2019-11-07 16:01:00 Affimed Announces FDA Clearance of IND to Commence First-in-Human Phase 1/2a Study of AFM24 for the Treatment of EGFR-Expressing Cancers
While looking at the support and resistance lines, it becomes clear the support lines are more consolidated while the resistance lines have a larger spread. This leave an interpretation that there's much more room for AFMD to grow rather than to fall. Additionally, beyond the technicals the EPS for the previous quarter left investors shocked because of the...
While analyzing the current support and resistance lines, I believe Affimed is ready to soar higher over the coming weeks. It's also worth noting that the recent EPS for the last quarter was significantly higher than the expected, leaving a lasting and big surprise for investors. Meanwhile, Affimed has presented at several conferences and proved that big news is...